Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.46 +0.3%	$2.61	$1.60 ▼ $16.55	$256.83M	1.09	1.09 million shs	1.01 million shs
INO Inovio Pharmaceuticals	$1.96 +0.5%	$1.96	$1.42 ▼ $12.33	$71.51M	1.34	628,304 shs	773,501 shs
NYXH Nyxoah	$7.71 -0.1%	$6.91	$5.55 ▼ $11.87	$262.95M	1.65	75,033 shs	42,833 shs
SNWV Sanuwave Health	$33.68 +2.1%	$29.74	$5.17 ▼ $39.50	$282.33M	1.19	58,393 shs	604,009 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	0.00%	+7.14%	+21.91%	+36.90%	-71.08%
INO Inovio Pharmaceuticals	0.00%	-6.25%	-8.45%	+1.56%	-77.22%
NYXH Nyxoah	0.00%	+2.12%	+0.26%	-32.04%	-7.32%
SNWV Sanuwave Health	0.00%	+6.49%	+9.67%	-12.26%	+3,299,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	2.9793 of 5 stars	3.6	3.0	0.0	0.0	3.6	2.5	0.0
INO Inovio Pharmaceuticals	3.6599 of 5 stars	3.3	2.0	0.0	4.3	2.8	0.0	0.6
NYXH Nyxoah	2.3727 of 5 stars	3.5	3.0	0.0	0.0	2.2	0.8	0.6
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.20	Buy	$12.63	264.88% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	397.45% Upside
NYXH Nyxoah	3.00	Buy	$14.50	88.07% Upside
SNWV Sanuwave Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INO, CATX, SNWV, and NYXH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/21/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/7/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $10.00
3/31/2025	CATX Perspective Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/27/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $15.00
3/26/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	$1.43M	179.60	N/A	N/A	$2.67 per share	1.30
INO Inovio Pharmaceuticals	$220K	326.70	N/A	N/A	$1.90 per share	1.03
NYXH Nyxoah	$4.89M	53.70	N/A	N/A	$3.60 per share	2.14
SNWV Sanuwave Health	$32.63M	8.84	N/A	N/A	($1.49) per share	-22.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
NYXH Nyxoah	-$64.10M	-$2.13	N/A	N/A	N/A	-1,571.39%	-63.37%	-46.67%	8/5/2025 (Estimated)
SNWV Sanuwave Health	-$31.37M	-$4.56	N/A	∞	N/A	-89.86%	N/A	-145.76%	N/A

Latest INO, CATX, SNWV, and NYXH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NYXH Nyxoah	-$0.49	-$0.63	-$0.14	-$0.63	$1.64 million	$1.12 million
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/9/2025	Q1 2025	SNWV Sanuwave Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
INO Inovio Pharmaceuticals	N/A	2.63	2.63
NYXH Nyxoah	0.22	3.59	3.35
SNWV Sanuwave Health	N/A	0.40	0.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
INO Inovio Pharmaceuticals	26.79%
NYXH Nyxoah	N/A
SNWV Sanuwave Health	42.53%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
INO Inovio Pharmaceuticals	2.30%
NYXH Nyxoah	17.11%
SNWV Sanuwave Health	36.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
NYXH Nyxoah	110	34.06 million	28.23 million	Not Optionable
SNWV Sanuwave Health	40	8.56 million	5.43 million	N/A

INO, CATX, SNWV, and NYXH Headlines

Recent News About These Companies

Financial Survey: ReShape Lifesciences (OTCMKTS:RSLSD) versus SANUWAVE Health (NASDAQ:SNWV)

June 14, 2025 | americanbankingnews.com

Analyzing SANUWAVE Health (NASDAQ:SNWV) and ReShape Lifesciences (OTCMKTS:RSLSD)

June 13, 2025 | americanbankingnews.com

Sanuwave: High Growth Wound Care Tech Primed For A Breakout

June 11, 2025 | seekingalpha.com

SANUWAVE Health, Inc. (NASDAQ:SNWV) COO Sells $51,596.02 in Stock

June 9, 2025 | marketbeat.com

Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

June 3, 2025 | globenewswire.com

SANUWAVE Health, Inc. (SNWV): A Bull Case Theory

May 30, 2025 | insidermonkey.com

Sanuwave Health Appoints Greg Bazar to Board of Directors

May 28, 2025 | globenewswire.com

Sanuwave Health Selected for Inclusion in Russell 2000Â® Index

May 28, 2025 | globenewswire.com

SANUWAVE Health (NASDAQ:SNWV) Cut to Hold at Wall Street Zen

May 26, 2025 | marketbeat.com

Insider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of Stock

May 17, 2025 | insidertrades.com

SANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Sanuwave Announces Q1 FY2025 Financial Results

May 9, 2025 | globenewswire.com

Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results

May 5, 2025 | globenewswire.com

SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO, CATX, SNWV, and NYXH Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.46 +0.01 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 -0.04 (-1.04%)

As of 07:56 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Inovio Pharmaceuticals NASDAQ:INO

$1.96 +0.01 (+0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.26%)

As of 07:49 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Nyxoah NASDAQ:NYXH

$7.71 -0.01 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$7.54 -0.17 (-2.26%)

As of 07:27 PM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Sanuwave Health NASDAQ:SNWV

$33.68 +0.68 (+2.06%)

As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time